Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children.
EBV-associated post transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication that may occur after hemopoietic SCT. We prospectively screened 80 children on a weekly basis using nested quantitative PCR to evaluate EBV genome copies. EBV viral load <1000 copies per 10(5) PBMC was observed in 63% of transplants, whereas it was between 1000 and 9999 copies per 10(5) PBMC in 13%, and between 10 000 and 19 999 in 10%, with no significant increase in percentage of CD20+ lymphocytes. Viral load reached > or = 20 000 copies per 10(5) PBMC in 14% of patients, and rituximab was administered to 75% of them. None of the patients except one developed a lymphoproliferative disease. Our study found that only 13% of unrelated donor HSCT recipients had a very high risk of EBV-PTLD defined as > or = 20 000 geq per 10(5) PBMC associated with an increase in CD20+ lymphocyte. We suggest that rituximab could be administered in the presence of very high levels of EBV-DNA viral load or in the presence of mid levels of EBV-DNA viral load associated with an increase in the percentage of CD20+ lymphocytes. Through this approach, we significantly reduced the number of patients treated with rituximab, and consequently the acute and chronic adverse events related to this treatment.
Hemopoietic Stem cell Transplant Unit, Hematology-Oncology Department, G Gaslini Children's Research Institute, Genova, Italy. maurafaraci@ospedale-gaslini.ge.it
M
M
Faraci
I
I
Caviglia
G
G
Morreale
E
E
Lanino
D
D
Cuzzubbo
S
S
Giardino
E
E
Di Marco
C
C
Cirillo
F
F
Scuderi
S
S
Dallorso
P
P
Terranova
C
C
Moroni
E
E
Castagnola
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D001402:B-Lymphocytes / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D004279:DNA, Viral / Q000097:blood; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D018655:Lymphocyte Count; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000517:prevention & control; D008297:Male; D011446:Prospective Studies; D000069283:Rituximab; D014184:Transplantation, Homologous; D019562:Viral Load; D014775:Virus Activation
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D004279:DNA, Viral; D000069283:Rituximab